

This is a reprint from ECTRIMS 2021 virtual congress, which was originally published in Switzerland; the references to “Merck” or “Merck KGaA” within refer to (1) Merck KGaA, Darmstadt, Germany; (2) an affiliate of Merck KGaA, Darmstadt, Germany; or (3) one of the businesses of Merck KGaA, Darmstadt, Germany, which operate as EMD Serono in the healthcare, MilliporeSigma in the life science and EMD Electronics in the electronics business in the U.S. and Canada.

There are two different, unaffiliated companies that use the name “Merck”. Merck KGaA, Darmstadt, Germany, which is providing this content, uses the firm name “Merck KGaA, Darmstadt, Germany” and the business names EMD Serono in the healthcare, MilliporeSigma in the life science and EMD Electronics in the electronics business in the U.S. and Canada. The other company, Merck & Co., Inc. holds the rights in the trademark “Merck” in the U.S. and Canada. Merck & Co., Inc. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the “Merck” trademark in all other countries of the world.

Post-approval Safety of Cladribine Tablets With Particular Reference to COVID-19 Outcomes: An Update



GET POSTER PDF
Copies of this poster obtained through QR (Quick Response) code are for personal use only and may not be reproduced without written permission of the authors

G. Giovannoni¹, J. Berger², T. Leist³, D. Jack⁴, A. Galazka⁵, A. Nolting⁶, D. Damian⁷

¹Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; ²Perelman School of Medicine, University of Pennsylvania, Department of Neurology, Philadelphia, PA, USA; ³Jefferson University, Comprehensive MS Center, Division of Clinical Neuroimmunology, Philadelphia, PA, USA; ⁴Merck Serono Ltd, Feltham, UK (an affiliate of Merck KGaA); ⁵Ares Trading S.A., Eysins, Switzerland (an affiliate of Merck KGaA); ⁶Merck Healthcare KGaA, Darmstadt, Germany; ⁷EMD Serono Inc., Billerica, MA, USA (an affiliate of Merck KGaA)

US-MAV-01386
October 2021

CONCLUSIONS



Regarding COVID-19, patients treated with cladribine tablets are generally not at greater risk of serious disease and/or a severe outcome compared with the general population and other patients with MS who acquired COVID-19.



The post-approval safety profile of cladribine tablets is consistent with previously published safety findings from the clinical development program.

INTRODUCTION

- The safety profile of cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) from the clinical development program for relapsing multiple sclerosis (MS) is well characterized.^[1]
- Additional real-life safety data have accrued since the approval of cladribine tablets in >80 countries worldwide.

OBJECTIVES



To update on the post-approval safety profile of cladribine tablets in patients with relapsing MS, with particular reference to COVID-19.

METHODS

- We previously reported on outcomes for cladribine tablets-treated patients with relapsing MS and confirmed or suspected COVID-19 (as of 29 June 2020 and 15 January 2021, respectively).^[2,3]
- An update on these findings is provided, as of 15 July 2021, based on cases reported to the Merck Global Patient Safety Database.
 - Cases meeting the criteria of hospitalized, medically significant (as specified by the case reporter), or fatal were designated as serious

- Outcomes were classified as per usual pharmacovigilance practice
- Time to onset of COVID-19 from the most recent annual treatment course with cladribine tablets was also evaluated
- A summary of post-approval, real-world adverse events (AEs) is also provided.

RESULTS

Summary of COVID-19 Cases (as of 15 July 2021)

- The safety database included 503 reported cases of COVID-19 in cladribine tablets-treated patients.
- Six additional patients had symptoms compatible with COVID-19 but were not evaluated further since they were subsequently reported to have negative PCR tests.

	All patients (n=503)	Serious COVID-19 (n=68)
Median age, years (range)	41 (17–73)	48 (24–73)
Aged ≥60 years, n (%)	27 (5.4)	8 (11.8)
Not reported, n (%)	89 (17.7)	3 (4.4)
Sex, n (%)		
Male	101 (20.1)	16 (23.5)
Female	339 (67.4)	50 (73.5)
Not reported	63 (12.5)	2 (2.9)
Confirmed COVID-19, ^a n (%)	316 (62.8)	51 (75.0)

^aAccording to PCR test or serology.

Cases meeting the criteria of hospitalized, medically significant (as specified by the case reporter), or fatal were designated as serious.

PCR, polymerase chain reaction.


Summary of Adverse Events (as of 7 July 2021)

- To date, 35,668 patients have received cladribine tablets post-approval (49,783.5 patient-years of exposure).
- Adjusted incidences per 100 patient-years for AEs of special interest:
 - Severe lymphopenia (72 cases), 0.14 (95% CI: 0.11–0.18)
 - Herpes zoster (362 cases), 0.73 (95% CI: 0.66–0.81)
 - Tuberculosis (16 cases), 0.03 (95% CI: 0.02–0.05)
 - Severe infections (479 cases), 0.96 (95% CI: 0.88–1.05)
 - Progressive multifocal leukoencephalopathy, 0
 - Opportunistic infections (9 cases), 0.02 (95% CI: 0.01–0.03)
 - Malignancies (108 cases), 0.22 (95% CI: 0.18–0.26)
 - Congenital anomalies (2 cases),^a 0.004 (95% CI: 0.001–0.016)

^aIn one case of maternal exposure during pregnancy reported by a health authority, an elective termination was performed due to an unspecified congenital anomaly of the fetus after cladribine exposure in the third trimester. In the second spontaneous case of maternal exposure (2 months) before pregnancy, a live birth with congenital anomaly (microduplication of chromosome 16p11.2) was reported.

Summary of COVID-19 Outcomes (as of 15 July 2021)

- Of 503 evaluable patients, 259 (51.5%) were recovered/recovering at the time of reporting.
- Among 68 serious cases, 47 (69.1%) were recovered/recovering at the time of reporting.
 - One patient (suspected COVID-19) required mechanical ventilation
 - There were 3 fatalities (0.6% of all patients; all had suspected COVID-19)
 - One patient died in late 2020 having experienced pneumonia and renal failure
 - One patient died in early 2021 (no further details reported)
 - One patient died in early 2021 having experienced stroke complicated by pneumonia
- Median (range) time to onset of COVID-19 from most recent treatment course:
 - All patients, 169 (0–684) days (n=314)
 - Serious cases, 184 (4–643) days (n=52)



Cases meeting the criteria of hospitalized, medically significant (as specified by the case reporter), or fatal were designated as serious. For simplicity of presentation, the outcome 'not reported' also includes those with missing or pending outcomes.

REFERENCES

1. Cook S, et al. *Mult Scler Relat Disord.* 2019;29:157–167. 2. Jack D, et al. *Mult Scler Relat Disord.* 2020;46:102469. 3. Jack D, et al. *Mult Scler Relat Disord.* 2021;51:102929.

Disclosures: GG has received speaker honoraria and consulting fees from AbbVie, Actelion (Janssen/J&J), Almirall, Atara Bio, Bayer, Biogen, Celgene (BMS), FivePrime, GlaxoSmithKline, GW Pharma, Ironwood, Merck & Co., Novartis, Merck, Pfizer Inc., Protein Discovery Laboratories, Roche, Sanofi -Genzyme, Teva Pharmaceutical Industries Ltd, UCB, and Vertex Pharmaceuticals; and has received research support unrelated to this study from Biogen, Ironwood, Merck & Co., Novartis, and Takeda. JB has received honoraria as a Scientific Advisory Board member for Inhibikase and Novartis; has received consultancy fees from Amgen, Celgene (BMS), Dr. Reddy's Laboratories, EMD Serono (an affiliate of Merck KGaA), Encycle, Excision Bio, Genzyme, MAPI, Merck, Millennium/Takeda, Morphic, and Shire; and has received honoraria and institutional grants for consultancy from Biogen and Roche/Genentech. TL has received consultancy fees or clinical research grants from Acorda, Bayer, Biogen, Daiichi, EMD Serono (an affiliate of Merck KGaA), Novartis, ONO, Pfizer, and Teva Neuroscience. DJ is an employee of Merck Serono Ltd, Feltham, UK (an affiliate of Merck KGaA). AG was an employee of Ares Trading S.A., Eysins, Switzerland (an affiliate of Merck KGaA) at the time of the study, and is currently a consultant to Merck. AN is an employee of Merck Healthcare KGaA, Darmstadt, Germany. DD is an employee of EMD Serono Inc., Billerica, MA, USA (an affiliate of Merck KGaA).

Medical writing assistance was provided by Steve Winter of inScience Communications, Springer Healthcare Ltd, UK, and was funded by Merck Healthcare KGaA, Darmstadt, Germany.

Presented at ECTRIMS 2021 Virtual Congress | 13–15 October

Data collection and analysis was sponsored by Merck (CrossRef Funder ID: 10.13039/100009945)

FOR REACTIVE MEDICAL USE ONLY